SARAWAK GENERAL HOSPITAL JOINS IQVIA’S ​NETWORK OF GLOBALLY ​QUALIFIED PHASE I ONCOLOGY SITES

NOV 26,2018 6.11 PM
 
Picture
Clinical Research Malaysia at Sa​rawak General Hospital is the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites.
Clinical Research Malaysia (CRM) recently signed a memorandum of understanding (MoU) to establish a strategic alliance with IQVIA’s global Early Phase Oncology Network (EPON).

The agreement makes CRM at Sa​rawak General Hospital the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites. CRM, established by the Ministry of Health in 2012, exists to advance Malaysia’s ability to contribute to global health solutions. IQVIA is a leading global provider of contract research services, advanced analytics and technology solutions to the life-sciences industry.

“This agreement is a major step forward for the country of Malaysia to provide advanced Phase I studies for investigational cancer therapies,” said CRM Chief Executive Officer Dr Akhmal Yusof. 

“Advances in genomics offer new hope for targeted oncology products. Through this agreement, Sarawak General Hospital will join IQVIA’s global Early Phase Oncology Network, which is designed to provide fast, high-quality Phase I oncology studies to biopharmaceutical companies.”

IQVIA Asia Pacific President Anand Tharmaratnam said: “This agreement builds upon our long relationship with Clinical Research Malaysia as an IQVIA Prime Site.  Adding Sarawak General Hospital’s research centre gives biopharma companies, for the first time, a Southeast Asia location as part of IQVIA’s global network of high quality early phase oncology research sites.  This is a significant step forward in our joint mission to accelerate the development of targeted oncology therapies in Malaysia and Asia for the benefit of patients worldwide.”

IQVIA has been conducting oncology early clinical research in Asia Pacific for more than two decades. The IQVIA EPON-Clinical Research Malaysia strategic alliance is designed to streamline study startup, enhance consistency and deliver high-quality results faster.

This collaboration is intended to significantly improve the quality of early phase oncology trials in Malaysia by having innovative investigational therapies as an option for patients. 

​It aligns with the  Phase I Realization Project (P1RP) that was launched by CRM in 2016 which is focused in enhancing Malaysia’s early phase clinical research capacity and building a more attractive early phase clinical research ecosystem.